Clinical Trial Phases

PET Imaging and Radiolabeling Techniques in Phase 0 Oncology Studies

Posted on digi By digi

Phase 0 oncology trials aim to generate early human data to guide therapeutic development. One of the most powerful tools in these trials is Positron Emission Tomography (PET) imaging, especially when paired with radiolabeled compounds. PET enables researchers to visualize how a drug behaves in tumors, confirming whether it reaches the target, engages it, and stays long enough to exert an effect—all at microdose levels.
Click to read the full article.

Preclinical Studies

Combining Phase 0 with Adaptive Phase 1 Trials: Strategies for Seamless Transition

Posted on digi By digi

Phase 0 trials provide early human pharmacokinetic and target engagement data. Phase 1 trials explore safety and dose tolerance. Combining these phases into a seamless development strategy using adaptive trial designs offers speed, efficiency, and data continuity. This approach is especially valuable for high-risk, high-reward programs such as oncology, CNS, or rare disease pipelines.
Click to read the full article.

Phase 0 (Microdosing Studies)

Phase 0 vs. First-in-Human Trials: How to Transition Effectively

Posted on digi By digi

Phase 0 trials offer early insight into drug behavior in humans using sub-therapeutic microdoses. First-in-Human (FIH) trials, on the other hand, initiate therapeutic dosing to assess safety and tolerability. Bridging the gap between these two stages requires careful planning, regulatory awareness, and a clear understanding of pharmacology. This article explores the key distinctions and offers guidance on how to transition safely and effectively.
Click to read the full article.

Preclinical Studies

What are Phase 4 (Post-Marketing) Clinical Trials? A Complete Overview for Clinical Researchers

Posted on digi By digi

Phase 4 clinical trials, often referred to as post-marketing studies, are conducted after a drug or therapy has received regulatory approval and is available in the market. Unlike Phases 1 to 3, which focus on safety, efficacy, and dosing during the drug development process, Phase 4 trials evaluate how a product performs in the real world—outside of the controlled clinical trial environment.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

What Happens in a Phase 2 Clinical Trial?

Posted on digi By digi

Phase 2 clinical trials are a pivotal part of the drug development process. After a new drug or therapy demonstrates basic safety in Phase 1, it moves to Phase 2 to assess its effectiveness in treating a specific condition. These trials act as a critical bridge between early human testing and the large-scale confirmatory Phase 3 studies. In this tutorial, we’ll break down what happens in a Phase 2 clinical trial, how it’s designed, and why it’s essential for successful therapeutic advancement.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)

Differences Between Phase 3 and Phase 4 Trials: From Controlled Research to Real-World Practice

Posted on digi By digi

Clinical trials progress through a structured series of phases, with Phase 3 and Phase 4 being the final and most public-facing stages. While both generate critical evidence about a drug’s performance, they serve distinct purposes, involve different stakeholders, and follow unique regulatory and scientific frameworks.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Key Differences Between Phase 1 and Phase 2 Trials

Posted on digi By digi

Clinical trials are conducted in distinct phases, each with a specific purpose and methodology. Among these, Phase 1 and Phase 2 trials represent the critical early stages of human testing. Although they are often grouped under “early-phase development,” these two phases differ significantly in objectives, study population, trial design, duration, and outcomes. In this tutorial, we provide an in-depth comparison between Phase 1 and Phase 2 clinical trials to help clinical researchers, students, and industry professionals understand their unique roles.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)

Key Differences Between Phase 0 and Phase 1 Trials

Posted on digi By digi

Both Phase 0 and Phase 1 trials are part of early-phase clinical research, but they serve distinct purposes in drug development. Understanding their differences is critical for planning development strategies, regulatory submissions, and timelines. This article compares the two phases side-by-side to clarify how they fit into the larger clinical trial landscape.
Click to read the full article.

Phase 1 (Safety and Dosage)

Regulatory Expectations for Phase 4 Studies Globally: FDA, EMA, CDSCO, PMDA & More

Posted on digi By digi

Once a product receives regulatory approval and enters the market, its journey doesn’t end—rather, it transitions into a new phase: post-marketing surveillance, or Phase 4. Regulatory agencies across the globe require continued evaluation of a product’s safety, efficacy, and use in diverse populations. These studies are governed by varying regional regulations but share a common goal—ensuring that public health remains protected beyond clinical trial settings.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)